A Phase III Multicenter Randomized Double-Blind Placebo-Controlled Parallel-Group Efficacy and Safety Study of Crenezumab in Patients with Prodromal to Mild Alzheimer's Disease
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to compare the effects, good or bad, of crenezumab versus placebo (an inactive substance that looks like crenezumab).
Description
The purpose of this study is to evaluate crenezumab 60mg/kg compared with placebo when administered by intravenous (IV) infusion every 4 weeks over 100 weeks as measured by the global outcomes, as assessed by the Clinical Dementia Rating-Sum of Boxes at final outcome assessment at Week 105, 4 weeks after final dose.
Details
| Condition | Alzheimer's disease |
|---|---|
| Age | 50years - 85years |
| Clinical Study Identifier | TX6885 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.